Katz-Summercorn, A. C.
Jammula, S.
Frangou, A. http://orcid.org/0000-0001-6990-2756
Peneva, I.
O’Donovan, M.
Tripathi, M.
Malhotra, S.
di Pietro, M.
Abbas, S. http://orcid.org/0000-0002-2541-4969
Devonshire, G. http://orcid.org/0000-0002-1408-8176
Januszewicz, W. http://orcid.org/0000-0002-8200-2661
Blasko, A.
Nowicki-Osuch, K. http://orcid.org/0000-0003-3828-8620
MacRae, S.
Northrop, A.
Redmond, A. M. http://orcid.org/0000-0001-9070-1780
Wedge, D. C. http://orcid.org/0000-0002-7572-3196
Fitzgerald, R. C. http://orcid.org/0000-0002-3434-3568
Funding for this research was provided by:
RCUK | Medical Research Council (RG84269)
Cancer Research UK (RG81771/84119)
Wellcome Trust (203141/Z/16/Z)
Article History
Received: 15 July 2021
Accepted: 14 January 2022
First Online: 17 March 2022
Competing interests
: R.C.F. and M.O’.D. are named on patents related to Cytosponge and related assays (Cell Sampling Device PCT/GB2010/002077, Biomarker for Barrett’s Oesophagus US2012/0009597) which have been licensed by the Medical Research Council to Covidien GI Solutions (now Medtronic) and are co-founders of CYTED Ltd. R.C.F. and M.O’.D. have a patent on a method for detecting benign conditions in the upper intestinal tract (Methods for Detection of Benign Conditions PCT/GB2012/000855). These are not directly involved in the topic of this paper. The remaining authors declare no competing interests.